


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app16.us.archive.org';v.server_ms=2169;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Management of cytomegalovirus infection in haemopoietic stem cell transplantation. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712202937im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712202937im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712202937im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712202937im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712202937/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712202937im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712202937cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712202937js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712202937if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712202937/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712202937if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712202937/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712202937/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712202937/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712202937/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712202937/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712202937/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712202937/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712202937/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712202937/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712202937/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712202937/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712202937/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712202937/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712202937/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712202937/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712202937/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712202937/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712202937/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712202937/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712202937/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010001</li>
            <li>2013 Jul
            </li>            
                                </ul>
        <div>
                <h1>Management of cytomegalovirus infection in haemopoietic stem cell transplantation.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712202937/https://www.guideline.gov/search?f_Guideline_Developer_String=British%20Society%20for%20Haematology%20Guidelines&amp;fLockTerm=British%2BSociety%2Bfor%2BHaematology%2BGuidelines">British Society for Haematology Guidelines</a></li>
                        <li>   
                                <a id="1851" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A, British Committee for Standards in Haematology, British Society of Blood and Marrow Transplantation, UK Virology Network. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013 Jul;162(1):25-39. [146 references] <a href="https://web.archive.org/web/20180712202937/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23647436" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712202937im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180712202937/https://www.guideline.gov/Home/Disclaimer?id=47072&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fonlinelibrary.wiley.com%252fdoi%252f10.1111%252fbjh.12363%252fpdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712202937im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180712202937/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712202937/https://www.guideline.gov/search?f_ICD9CM_CUI=C0010823&amp;fLockTerm=Cytomegaloviral+disease">Cytomegaloviral disease</a>
 (078.5)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0001367&amp;fLockTerm=Acyclovir">Acyclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0003451&amp;fLockTerm=Antiviral+Agents">Antiviral Agents</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0010823&amp;fLockTerm=Cytomegalovirus+Infections">Cytomegalovirus Infections</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0070895&amp;fLockTerm=Foscarnet">Foscarnet</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0017066&amp;fLockTerm=Ganciclovir">Ganciclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0472699&amp;fLockTerm=Hematopoietic+Stem+Cell+Transplantation">Hematopoietic Stem Cell Transplantation</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0019633&amp;fLockTerm=Histocompatibility+Testing">Histocompatibility Testing</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0085297&amp;fLockTerm=Immunoglobulins%2c+Intravenous">Immunoglobulins, Intravenous</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0021079&amp;fLockTerm=Immunosuppression">Immunosuppression</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C1709846&amp;fLockTerm=Real-Time+Polymerase+Chain+Reaction">Real-Time Polymerase Chain Reaction</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0162802&amp;fLockTerm=Sequence+Analysis%2c+DNA">Sequence Analysis, DNA</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0036743&amp;fLockTerm=Serologic+Tests">Serologic Tests</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0042285&amp;fLockTerm=Valine">Valine</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MSH_CUI=C0376705&amp;fLockTerm=Viral+Load">Viral Load</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0001367&amp;fLockTerm=Acyclovir">Acyclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0003451&amp;fLockTerm=Antiviral+Agents">Antiviral Agents</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C1277794&amp;fLockTerm=Cytomegalovirus+IgG+Antibody+Measurement">Cytomegalovirus IgG Antibody Measurement</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0010823&amp;fLockTerm=Cytomegalovirus+Infections">Cytomegalovirus Infections</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0070895&amp;fLockTerm=Foscarnet">Foscarnet</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0017066&amp;fLockTerm=Ganciclovir">Ganciclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0019633&amp;fLockTerm=Histocompatibility+Testing">Histocompatibility Testing</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0085297&amp;fLockTerm=Immunoglobulins%2c+Intravenous">Immunoglobulins, Intravenous</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C1709846&amp;fLockTerm=Real-Time+Polymerase+Chain+Reaction">Real-Time Polymerase Chain Reaction</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0086930&amp;fLockTerm=Risk+Assessment">Risk Assessment</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0036743&amp;fLockTerm=Serologic+tests">Serologic tests</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0021079&amp;fLockTerm=Therapeutic+immunosuppression">Therapeutic immunosuppression</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0042285&amp;fLockTerm=Valine">Valine</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C1261478&amp;fLockTerm=Viral+load+measurement">Viral load measurement</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_MTH_CUI=C0376705&amp;fLockTerm=Viral+Load+result">Viral Load result</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712202937/https://www.guideline.gov/search?f_PDQ_CUI=C0001367&amp;fLockTerm=acyclovir">acyclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_PDQ_CUI=C0017066&amp;fLockTerm=ganciclovir">ganciclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_PDQ_CUI=C0021079&amp;fLockTerm=immunosuppression">immunosuppression</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_PDQ_CUI=C0249458&amp;fLockTerm=valacyclovir">valacyclovir</a>
, <a href="/web/20180712202937/https://www.guideline.gov/search?f_PDQ_CUI=C0909381&amp;fLockTerm=valganciclovir">valganciclovir</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001367&amp;fLockTerm=Acyclovir">Acyclovir</a>
 (372729009), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001367&amp;fLockTerm=Acyclovir">Acyclovir</a>
 (41193000), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001367&amp;fLockTerm=Acyclovir">Acyclovir</a>
 (425884003), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003451&amp;fLockTerm=Antiviral+agent">Antiviral agent</a>
 (32249005), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003451&amp;fLockTerm=Antiviral+agent">Antiviral agent</a>
 (372701006), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1277794&amp;fLockTerm=Cytomegalovirus+IgG+antibody+measurement">Cytomegalovirus IgG antibody measurement</a>
 (313604004), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010823&amp;fLockTerm=Cytomegalovirus+infection">Cytomegalovirus infection</a>
 (28944009), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0070895&amp;fLockTerm=Foscarnet">Foscarnet</a>
 (372902006), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0070895&amp;fLockTerm=Foscarnet">Foscarnet</a>
 (96099004), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0017066&amp;fLockTerm=Ganciclovir">Ganciclovir</a>
 (372848001), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0017066&amp;fLockTerm=Ganciclovir">Ganciclovir</a>
 (78025001), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
 (234336002), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0549171&amp;fLockTerm=Histocompatibility+crossmatch">Histocompatibility crossmatch</a>
 (72845001), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0021079&amp;fLockTerm=Immunosuppressive+therapy">Immunosuppressive therapy</a>
 (86553008), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0085297&amp;fLockTerm=Intravenous+immunoglobulin">Intravenous immunoglobulin</a>
 (350344000), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0086930&amp;fLockTerm=Risk+assessment">Risk assessment</a>
 (225338004), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0036743&amp;fLockTerm=Serologic+test">Serologic test</a>
 (68793005), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0249458&amp;fLockTerm=Valacyclovir">Valacyclovir</a>
 (324820003), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0249458&amp;fLockTerm=Valacyclovir">Valacyclovir</a>
 (96098007), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0909381&amp;fLockTerm=Valganciclovir">Valganciclovir</a>
 (129476000), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0909381&amp;fLockTerm=Valganciclovir">Valganciclovir</a>
 (395266000), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042285&amp;fLockTerm=Valine">Valine</a>
 (419086006), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042285&amp;fLockTerm=Valine">Valine</a>
 (72840006), <a href="/web/20180712202937/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1261478&amp;fLockTerm=Viral+load">Viral load</a>
 (395058002)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/downloadcontent/ngc-10001?contentType=pdf" class="pdf">.PDF 83.6 kb</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/downloadcontent/ngc-10001?contentType=word" class="word">Word Document 283.4 kb</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/downloadcontent/ngc-10001?contentType=xml" class="xml">.XML 34.4 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712202937/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712202937/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712202937/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712202937/mailto:/?Subject=AHRQ: Management of cytomegalovirus infection in haemopoietic stem cell transplantation.&amp;body=https://www.guideline.gov/summaries/summary/47072/management-of-cytomegalovirus-infection-in-haemopoietic-stem-cell-transplantation" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Management of cytomegalovirus infection in haemopoietic stem cell transplantation. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Jul 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072">RefWorks</a></li>
                            <li><a href="/web/20180712202937/https://www.guideline.gov/summaries/citedownload/47072?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47072" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions for the quality of the evidence (<strong>A&ndash;C</strong>) and strength of recommendations (strong [grade <strong>1</strong>], weak [grade <strong>2</strong>]) are given at the end of the "Major Recommendations" field.</p>
<p><strong>Background</strong></p>
<ul style="list-style-type: disc;">
    <li>Cytomegalovirus (CMV) infection and CMV disease should be diagnosed according to established, internationally accepted, standardized criteria (<strong>Grade 1C</strong>). </li>
    <li>Risk-adapted patient assessment should inform clinical management (<strong>Grade 1B</strong>). </li>
</ul>
<p><strong>Impact of Host and Donor CMV Serostatus</strong></p>
<ul style="list-style-type: disc;">
    <li>All potential haemopoietic stem cell transplantation (HSCT) recipients should be tested for the presence of CMV immunoglobulin G (IgG) antibody at diagnosis (<strong>Grade 1C</strong>). </li>
    <li>Once optimum human leucocyte antigen (HLA) matching has been performed, a CMV IgG-negative donor should be chosen for a CMV IgG-negative recipient and a CMV IgG-positive donor should be chosen for CMV IgG-positive recipient when possible (<strong>Grade 1A</strong>). </li>
    <li>Donors or recipients who are initially found to be CMV IgG-negative should be retested pre-transplant to exclude primary CMV infection (<strong>Grade 1C</strong>). </li>
    <li>Apparent CMV seroconversion in potential allograft recipients who have received unscreened blood products should be actively investigated to exclude passively acquired antibody (<strong>Grade 1C</strong>). </li>
    <li>Any CMV IgG-negative HSCT recipient transplanted from a CMV IgG-negative donor who develops CMV infection post-transplant must be reported to the Serious Hazards of Transfusion (SHOT) (<strong>Grade 1C</strong>). </li>
</ul>
<p><strong>Primary and Secondary Prophylaxis for CMV</strong></p>
<ul style="list-style-type: disc;">
    <li>Primary prophylaxis with ganciclovir is not generally recommended as toxicity outweighs efficacy in HSCT patients (<strong>Grade 1B</strong>). </li>
    <li>Primary prophylaxis with aciclovir or valaciclovir can be deployed but only in conjunction with appropriate monitoring of CMV in the blood (<strong>Grade 1B</strong>). </li>
    <li>Valaciclovir or valganciclovir are valid treatment options for secondary prophylaxis with appropriate monitoring of CMV in the blood (<strong>Grade 1C</strong>). </li>
    <li>Intravenous immunoglobulins are not recommended for prophylaxis of CMV infection (<strong>Grade 1A</strong>). </li>
</ul>
<p><strong>Pre-emptive Therapy</strong></p>
<ul style="list-style-type: disc;">
    <li>Real-time quantitative polymerase chain reaction (PCR) is the preferred option for monitoring CMV deoxyribonucleic acid (DNA) levels in HSCT patients (<strong>Grade 1B</strong>). </li>
    <li>All diagnostic laboratories should deploy the CMV international standard to allow CMV DNA loads to be compared between centres (<strong>Grade 1C</strong>). </li>
    <li>Monitoring of CMV DNA load should be undertaken at least weekly for the first 3 months post-HSCT (<strong>Grade 2C</strong>). </li>
    <li>CMV viral load monitoring should continue to 6&ndash;12 months if the patient has chronic graft-versus-host disease (GvHD) or prolonged T-cell immunodeficiency (<strong>Grade 1B</strong>). </li>
</ul>
<p><em>Treatment Thresholds</em></p>
<p>Each transplant centre should have a risk-adapted policy detailing threshold values for treatment of CMV infection, taking into account patient factors and local PCR methodology (<strong>Grade 2C</strong>).</p>
<p><em>Antiviral Agents Used in Pre-emptive Therapy</em></p>
<ul style="list-style-type: disc;">
    <li>Ganciclovir is recommended as first line pre-emptive therapy for CMV in HSCT patients (<strong>Grade 1A</strong>). </li>
    <li>Oral valganciclovir is a useful alternative when gastrointestinal absorption is normal or minimally impaired (<strong>Grade 1B</strong>). </li>
    <li>Foscarnet is recommended as an alternative first line agent if neutropenia is present or for ganciclovir treatment failures (<strong>Grade 1A</strong>). </li>
    <li>Pre-emptive therapy with cidofovir can be considered as third line in patients unresponsive or intolerant of a ganciclovir preparation or foscarnet (<strong>Grade 2B</strong>). </li>
</ul>
<p><em>Switching Pre-emptive Therapy</em></p>
<p>In patients where CMV DNA loads in blood increase by 1 log<sub>10</sub> over 2 weeks of pre-emptive therapy with a first line drug, an alternative agent and drug resistance profiling should be considered (<strong>Grade 2C</strong>).</p>
<p><em>Antiviral Drug Resistance</em></p>
<ul style="list-style-type: disc;">
    <li>Drug resistance should be considered if the CMV DNA load in blood fails to respond after 14 days of therapy, especially in non-lymphopenic or multiply pre-treated patients (<strong>Grade 2C</strong>). </li>
    <li>Sequence analysis of the UL97 and UL54 genes is the preferred option for monitoring resistance to currently available drugs (<strong>Grade 1B</strong>). </li>
</ul>
<p><strong>Management of CMV Disease</strong></p>
<ul style="list-style-type: disc;">
    <li>A multidisciplinary approach to management of CMV disease is required (<strong>Grade 1C</strong>). </li>
    <li><em>De novo</em> CMV disease should be treated with ganciclovir or foscarnet, plus intravenous immunoglobulin (<strong>Grade 1B</strong>). </li>
    <li>CMV disease that develops while on pre-emptive therapy or is clinically progressive requires drug resistance testing, increased drug doses and/or a change of drug (<strong>Grade 1B</strong>). </li>
    <li>Reduction in immunosuppression, especially corticosteroid dosage, is strongly recommended (<strong>Grade 1B</strong>). </li>
</ul>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong>:</p>
<p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong> Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong> Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong> Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series, or just opinion.</p>
<p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Cytomegalovirus infection in haemopoietic stem cell transplantation</p>
<p class="Note"><strong>Note</strong>: The guidelines also are relevant to other areas of haematological oncology where there is an increased risk of cytomegalovirus infection, such as haematological cancers where intense anti-T-cell therapy has been deployed.</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Diagnosis</p>
                    <p>Management</p>
                    <p>Prevention</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Hematology</p>
                    <p>Infectious Diseases</p>
                    <p>Internal Medicine</p>
                    <p>Medical Genetics</p>
                    <p>Oncology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To expand and adapt previous guidance on management of cytomegalovirus infection in haemopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Patients with cytomegalovirus infection in haemopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Assessment/Diagnosis</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Diagnosis according to established, internationally accepted criteria </li>
    <li>Risk-adapted patient assessment </li>
    <li>Testing for the presence of cytomegalovirus (CMV) immunoglobulin G (IgG) antibody </li>
    <li>Investigation of CMV seroconversion </li>
    <li>Optimum human leucocyte antigen (HLA) matching for donors </li>
</ol>
<p><strong>Prevention/Management/Treatment</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Ganciclovir </li>
    <li>Aciclovir </li>
    <li>Valaciclovir </li>
    <li>Valganciclovir </li>
    <li>Intravenous immunoglobulin </li>
    <li>Real-time quantitative polymerase chain reaction (PCR) </li>
    <li>CMV viral load monitoring </li>
    <li>Foscarnet </li>
    <li>Sequence analysis of the UL97 and UL54 genes for drug resistance screening </li>
    <li>Reduction in immunosuppression </li>
</ol></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Signs and symptoms of cytomegalovirus (CMV) infection </li>
    <li>Risk factors of CMV infection (e.g., measured by incidence of transfusion-transmitted CMV infection, incidence of CMV reactivation, incidence of CMV-related complications, survival/mortality) </li>
    <li>Effectiveness of CMV prevention (e.g., measured by CMV infection, CMV reactivation) </li>
    <li>Sensitivity and accuracy of diagnostic tests </li>
    <li>Efficacy/effectiveness of treatments (e.g., measured by response rates, resistance rates, progression to CMV, survival) </li>
    <li>Treatment-related toxicity </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>The production of these guidelines involved literature review to 1 May 2012 including Medline, PubMed, and Cochrane reviews databases.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong> Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong> Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong> Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series, or just opinion.</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence (see the "Rating Scheme for the Strength of the Evidence" field).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>The production of these guidelines involved the following steps:</p>
<ul style="list-style-type: disc;">
    <li>Establishment of a working group comprising experts in the field of allogeneic transplantation and clinical virology. </li>
    <li>Development of key recommendations based on randomized, controlled trial evidence. Due to the paucity of randomized studies, some recommendations are based on literature review and a consensus of expert opinion. </li>
    <li>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to assess the strength of recommendations (see the "Rating Scheme for the Strength of the Recommendations" field). </li>
</ul></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The production of these guidelines involved the following steps:</p>
<ul style="list-style-type: disc;">
    <li>Initial review of manuscript, performed by the UK Clinical virology Network, British Society of Blood and Marrow Transplantation executive committee, and the British Committee for Standards in Haematology (BCSH) Haem-Onc Task Force. </li>
    <li>Final review by sounding boards of the British Society for Haematology and British Society of Blood and Marrow Transplantation. </li>
</ul></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate prevention and management of cytomegalovirus infection in haemopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p><strong>Drugs Used for Cytomegalovirus (CMV) Prevention</strong></p>
<ul style="list-style-type: disc;">
    <li>Ganciclovir prophylaxis significantly reduced the incidence of CMV infection and disease during the period of prophylaxis. However neutropenia occurred in up to 30% of cases treated and infective complications were increased. </li>
    <li>Prolonged exposure of CMV to ganciclovir, especially in the setting of T-cell depletion, may encourage resistance, as occurs in solid organ transplantation. </li>
    <li>Routine use of aciclovir or valaciclovir for CMV prophylaxis is relatively non-toxic but will result in some patients being overtreated. </li>
</ul>
<p><strong>Side Effects of Drugs Used to Treat CMV Infection</strong></p>
<ul style="list-style-type: disc;">
    <li>Ganciclovir: myelosuppression </li>
    <li>Valganciclovir: haemolysis, nausea/vomiting, fever, rash, mental state changes, urinary symptoms </li>
    <li>Foscarnet: electrolyte abnormalities, renal impairment, nausea/vomiting, genitourinary, urinary symptoms </li>
    <li>Cidofovir: renal impairment, nausea/vomiting, ocular </li>
    <li>In 1 study (which compared 60 mg/kg foscarnet with ganciclovir 5 mg/kg), renal insufficiency was more common with foscarnet and myelosuppression with ganciclovir. </li>
</ul></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>These evidence-based guidelines expand and adapt previous guidance. While specifically focusing on allogeneic haemopoietic stem cell transplantation (HSCT), they are relevant to other areas of haematological oncology where there is an increased risk of cytomegalovirus (CMV) infection, such as haematological cancers where intense anti-T-cell therapy has been deployed.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Staying Healthy</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Patient-centeredness</p>
                    <p>Safety</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A, British Committee for Standards in Haematology, British Society of Blood and Marrow Transplantation, UK Virology Network. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013 Jul;162(1):25-39. [146 references] <a href="https://web.archive.org/web/20180712202937/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23647436" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712202937im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>These evidence-based guidelines expand and adapt previous guidance:</p>
<ul style="list-style-type: disc;">
    <li>Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA &amp; Boeckh MJ. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of Blood and Marrow Transplantation. 2009;15:1143&ndash;1238. </li>
    <li>Andrews PA, Emery VC &amp; Newstead C. Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation. 2011;92:1181&ndash;1187. </li>
</ul></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Jul</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>British Society for Haematology Guidelines - Professional Association</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>British Committee for Standards in Haematology</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>British Committee for Standards in Haematology</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Authors</em>: Vincent Emery, Department of Virology, University College London School of Life and Medical Sciences, London; Mark Zuckerman, Department of Virology, King's College Hospital, London; Graham Jackson, Department of Haematology, Freeman Road Hospital, Newcastle; Celia Aitken, West of Scotland specialist virology centre, Gartnavel General Hospital, Glasgow; Husam Osman, Birmingham HPA Laboratory, Birmingham Heartlands Hospital, Birmingham; Anthony Pagliuca, Department of Haematology, King's College Hospital, London; Mike Potter, Section of Haemato-oncology, The Royal Marsden NHS Foundation Trust, London; Karl Peggs, Department of Haematology, University College London Hospitals, London; Andrew Clark, Blood and Marrow Transplant Unit, Beatson Oncology Centre, Glasgow, UK</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>The authors report no conflicts of interest.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: Available from the <a href="/web/20180712202937/https://www.guideline.gov/Home/Disclaimer?id=47072&amp;contentType=summary&amp;redirect=http%3a%2f%2fonlinelibrary.wiley.com%2fdoi%2f10.1111%2fbjh.12363%2fpdf" title="British Journal of Haematology Web site">British Journal of Haematology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712202937im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the British Committee for Standards in Haematology; Email: <a href="https://web.archive.org/web/20180712202937/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on October 18, 2013.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: <a href="https://web.archive.org/web/20180712202937/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a>.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712202937/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712202937/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712202937/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712202937/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712202937/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712202937/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712202937/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712202937/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712202937/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712202937/https://www.guideline.gov/disclaimer?id=47072&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712202937/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712202937/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712202937/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712202937/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712202937/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712202937/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712202937/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712202937/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712202937/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712202937/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712202937/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712202937/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712202937/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712202937/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712202937im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712202937/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712202937/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712202937js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712202937js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 20:29:37 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 16:56:34 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 1910.91 (3)
  esindex: 0.011
  captures_list: 1937.076
  CDXLines.iter: 18.989 (3)
  PetaboxLoader3.datanode: 83.405 (4)
  exclusion.robots: 0.284
  exclusion.robots.policy: 0.267
  RedisCDXSource: 0.856
  PetaboxLoader3.resolve: 1998.61 (2)
  load_resource: 198.763
-->